Linx denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for linx are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Linx
## Why Cigna Denied the LINX Device as Duplicate Therapy
Cigna's duplicate-therapy denial means the reviewer concluded that another treatment already authorized or in use serves the same clinical purpose as the LINX Reflux Management System. For GERD patients, this typically means Cigna is pointing to proton pump inhibitor (PPI) therapy or a prior fundoplication as the "equivalent" intervention. This denial is worth challenging because LINX and long-term PPI therapy address the underlying mechanical failure of the lower esophageal sphincter in fundamentally different ways, and for patients who have failed or cannot tolerate medical management, they are not interchangeable.
## Why This Denial Is Appealable
A duplicate-therapy denial does not withstand scrutiny when the clinical record documents that (a) the existing therapy has failed, caused intolerable side effects, or is medically contraindicated, and (b) the proposed device addresses a mechanism the existing therapy does not. Your prescriber's medical-necessity letter should explicitly distinguish the LINX device from prior treatments tried and explain why they are not clinically equivalent for your specific case.
## Federal Appeal Framework
- Internal appeal: You have the right to a full internal appeal under ERISA §503 (employer plans) or ACA §2719 (marketplace/insured plans). Submit within the deadline shown on your denial letter — typically 180 days.
- External review: If the internal appeal fails, you may request an independent external review by an accredited Independent Review Organization (IRO). Under ACA §2719, most denials of coverage must be eligible for external review. The external review request window is generally 4 months from the final internal denial, but confirm the exact deadline on your Explanation of Benefits.
- Expedited option: If delay would seriously jeopardize your health, request expedited external review; decisions are typically required within 72 hours.
## Documentation to Gather
1. Diagnosis confirmation — endoscopy/pH-impedance study results, manometry findings, and clinical notes establishing chronic GERD with objective evidence. 2. Prior-treatment history — a dated, outcome-specific log of every PPI and other medication tried, including duration, doses attempted (from your chart), and documented reason for failure or intolerance. 3. Clinical severity — symptom burden scores, quality-of-life impact, and any complications (e.g., esophagitis grade, Barrett's findings) documented in the chart. 4. Prescriber medical-necessity letter — must explain why LINX is not duplicative of the existing therapies and why continuing the prior therapy is inadequate for you specifically. 5. Applicable guidelines — reference the relevant gastroenterology society guidelines (e.g., SAGES, ACG) generically to support the clinical rationale; do not cite specific numbers from them.
## Criteria-Mapping Structure
Pull Cigna's published coverage policy for surgical GERD treatment and list every requirement side by side with your chart evidence. For each criterion Cigna states, document the exact chart fact that satisfies it. If the prior therapy Cigna cites as a duplicate is documented as failed or contraindicated in your records, state that explicitly for each criterion. This one-to-one mapping is the most persuasive element of a successful appeal.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →